LATITUDE Psoriasis Studies

Steer Yourpsoriasis symptoms in a Different Direction

Steer Yourpsoriasis symptoms in a Different Direction

If your plaque psoriasis journey feels like a trip with no destination,

it may be time to explore a different path. The LATITUDE Psoriasis Studies are evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.

Did You Know?

People with psoriasis are more likely to experience other comorbidities, including heart disease, stroke, metabolic syndrome, and depression.1
Sometimes psoriasis symptoms are mild, but did you know that 1 in 5 people have a moderate to severe case?2 Researchers are looking for ways to help them.
Psoriasis can have a hidden impact on daily life. We see it. Evidence suggests that people of color with psoriasis, no matter how severe, experienced a greater quality-of-life impact.3
Psoriasis is likely to be underdiagnosed among people of color due to differences in how the disease presents.1 That’s why it’s important for people from all communities to be represented in clinical research.
It’s never too late to steer psoriasis symptoms in a different direction—psoriasis is seen in adults between the ages of 45 and 64 more than any other age group.2

Walk a different path toward potential psoriasis relief with the LATITUDE Psoriasis Studies.

You may be able to participate in the LATITUDE Psoriasis Studies if you:

Are 18 years of age or older
Were diagnosed with moderate to severe psoriasis at least 6 months ago
Are interested in an investigational oral (taken by mouth) treatment
Have not previously used Otezla®

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

Qualified participants will receive all study-related medications and study-related care at no cost. Participants may be compensated for travel and expenses. Health insurance is not required to participate.

What if you could potentially impact the 125 million people worldwide (2–3% of the entire population) with psoriasis?1 Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies.

Participation in clinical research for psoriasis has an impact on 125 million people worldwide (2-3% of the entire population) with psoriasis.1  Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies.

About the LATITUDE Psoriasis Studies

Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies. This program is evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.

The investigational treatment works by helping to control inflammatory signals known to contribute to the buildup of plaque psoriasis. Participants will receive the investigational treatment, Otezla®* (an approved oral treatment for moderate to severe plaque psoriasis), or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.

Participants originally assigned to placebo who still have active disease during the study will have the opportunity to switch to the investigational treatment. All study treatments will be given as oral pills.

* Otezla® is a registered trademark of Amgen Inc.

Neither participants nor the study staff will know if participants are receiving the investigational treatment, the approved oral treatment, or a placebo. Participants will attend up to 20 scheduled study visits over the course of about a year. 

© 2023–2024 Clinical Trial Media. All Rights Reserved.

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences. 

For more detailed information on the cookies we use, please check our Privacy Policy

By continuing to access this website, you are giving us consent to collect cookies.